Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / People / Neil F. McFarlane
Person

Neil F. McFarlane

Tracked across 2 events · 35 articles · First seen Jun 08, 2026 · Last active Aug 03, 2026

Sentiment
-15
Attention
4
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (2)
4 -30
Regulatory
Zevra CHMP Negative Opinion on Arimoclomol
On July 24, 2026, the European Union — European Medicines Agency's European Union — Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion on the Marketing Authorization Application for arimoclomol, branded Meplyffa,…
Impact: Neil F. McFarlane, Zevra's CEO, is implicated in the investigation due to his 2024 earnings call statement about arimoclomol's approval prospects. His statements are under scrutiny for potential misleading claims.
Jul 24, 2026 · 29 articles
3 0
Regulatory
Zevra Therapeutics Extends MIPLYFFA Patent
Impact: Neil F. McFarlane, as President and CEO of Zevra Therapeutics, expressed satisfaction with the strengthened intellectual property protection for MIPLYFFA.
Jun 08, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Neil F. McFarlane live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.